bullish

Seastar Medical Holding Corp (ICU) - Friday, Jul 25, 2025

411 Views27 Oct 2025 22:35
Syndicated
SUMMARY

Key points (machine generated)

  • SeaStar Medical is developing the Selective Cytopheretic Device (SCD) to treat critically ill patients with hyperinflammation.
  • The SCD has received FDA approval for pediatric acute kidney injury and is expected to generate interim data from its adult trial by late Q3 next year.
  • The company currently has $10 million in cash but may need to raise additional funds for growth and to support its adult trial.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x